SBC — SBC Medical Group Holdings Inc

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) — deep-value analysis

Analysis date: August 17, 2026 · Reference price: $3.66 (close 08.14.2026, yfinance) · Market cap: $375.4M · Shares: 102,576,943 · Reporting currency: USD (operations in JPY) · Auditor: MaloneBailey LLP, Tokyo (since 2023)

Primary sources: 10-K FY2025 filed 03.27.2026 · 10-Q Q1 2026 filed 05.14.2026 · 10-Q Q2 2026 filed 08.13.2026 · 10-K FY2024 filed 03.28.2025 · DEF 14A filed 05.28.2026 · 424B7 filed 04.17.2026 · 8-K/EX-99.1 of 08.13.2026 · the automated data pack · the research brief · Monte Carlo the Monte Carlo simulation.

---

Executive summary (1 page: thesis, estimated value, verdict)

SBC Medical Group Holdings is a management services organization (MSO) that collects franchise, procurement, management-services and equipment-leasing fees from a group of Japanese medical corporations operating aesthetic clinics under the “Shonan Beauty Clinic” brand. The figure that defines the company is neither margin nor growth: 91.5% of FY2025 revenue ($158,860,970 of $173,607,489) came from affiliated parties — medical corporations whose “members” (the holders of voting rights) are relatives of CEO Dr. Yoshiyuki Aikawa, who in turn controls 81.7% of SBC’s votes (10-K FY2025, Note 20 and the income statement, p. F-5; DEF 14A 05.28.2026). Service pricing is set, on both sides of the table, by the same person.

It’s not an abstraction. In April 2025 management revised the fee structure toward affiliated clinics; the effect was a 15.48% drop in consolidated revenue, from $205,415,542 to $173,607,489, with franchise revenue falling 24.72% and management-services revenue 44.22% (10-K FY2025, Item 7). In August 2026, the same management announced fee increases that “would be expected to add approximately $15 million annually” (release 08.13.2026, EX-99.1). Therefore, this company’s top line is not a market outcome; it’s an internal allocation decision between the pockets of the same owner. This is the core of the thesis and of the risk alike.

Beneath this layer, the underlying asset is healthy and cheap. The network has reached 287 locations (+34 y/y), 6.9 million visits over the trailing 12 months (+10%) and an average spend per visit of $287 (+9%) (EX-99.1, 08.13.2026). LTM operating margin is 37.3%, ROIC (after-tax EBIT / capital employed) is approximately 29.5%, and the balance sheet has $184.3M cash against $37.9M interest-bearing debt as of 06.30.2026 — $146.7M net cash, i.e. 39% of market cap. Enterprise value is therefore ~$229M for an asset generating ~$65M annual EBIT: 3.5× EV/EBIT. On the surface, absurdly cheap.

My FCF bridge (detail in the valuation chapter) starts from CFO and subtracts real capex (including advances for fixed assets, which the automated bridge doesn’t see) and lease principal, then normalizes for non-recurring gains and FX. Result: normalized owner earnings of $39.0 million — below the $60.6M of gross trailing-12-month FCFE (inflated by an $11.2M tax deferral in H1 2026 and by the end of the affiliated-party float drain) and above the gross average of the last three years ($26.6M, depressed by the same drain). The 10.4% yield on market cap is consistent with what brokers publish (2026 consensus: EPS $0.45, i.e. ~$46M net profit — my figure is 15% more conservative).

The triangulated valuation gives a range of $3.39–$5.97 per share, with a central point around $4.05–4.40. Monte Carlo over the mechanical DCF (20,000 scenarios, OE $39M, g1 6%, r 12%, gt 2%) returns a median intrinsic value of $5.97 and a 98.5% probability the stock is undervalued. This probability must be read correctly: it measures flow uncertainty, not the risk that the flows never reach the minority shareholder. The four models incorporating this latter risk (bear, EPV, governance-adjusted, own multiples) cluster between −7% and +26% MOS, with a median of +11%.

Verdict: SPECULATIVE-MONITOR. My calculated GBL score (the tracker doesn’t yet have one — see the final chapter) is 50.8%, in the MONITOR band. The cheapness is real and measurable; the discount is, however, earned, not mistaken. Documented in the filings, in just 18 months: two consecutive fiscal years with unremediated material weaknesses in internal control, exactly around the related-party transaction approval process; a $12,000,000 salary for the CEO in 2025 (23.5% of net profit); a $1.6M salary for the CEO’s mother, not timely identified as a related-party transaction; a plane sold to a CEO entity, later marked up $10.35M, booked to equity, not to profit; a subsidiary guarantee on the CEO’s personal debt; and — most tellingly — the company paid ~$1.3–1.4 million of the costs for the secondary offering through which the CEO sold 3.1 million of his shares in April 2026, while the company’s own $20M buyback program, authorized in December 2025, bought back zero shares in the first six months of 2026.

Position sizing must reflect that the thesis depends on the behavior of a single person, not a business model. A small position, with a clear tracking thesis: the first buyback actually executed from the $20M program would be the signal that validates the thesis; a new downward “fee structure revision” would be the signal that breaks it.

---